ORIGINAL RESEARCH article
Front. Pharmacol.
Sec. Drugs Outcomes Research and Policies
Volume 16 - 2025 | doi: 10.3389/fphar.2025.1616942
Cost-effectiveness analysis of toripalimab plus chemotherapy versus standard chemotherapy in first-line treatment for extensive-stage small cell lung cancer: perspectives from the United States and China
Provisionally accepted
- Nanxishan Hospital of Guangxi Zhuang Autonomous Region, Gulin, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Toripalimab combined with chemotherapy has demonstrated significant clinical advantages in improving overall survival compared with chemotherapy alone as a first-line treatment for extensive-stage small-cell lung cancer (ES-SCLC).An economic evaluation was conducted using a Markov state-transition model to reflect the perspectives of the US payer and Chinese healthcare systems. Primary In contrast, in the US, the additional cost led to unfavorable ICERs of $842,855.23, $328,694.61, and $520,412.03 per QALY for the overall population, the ITH-L subgroup, and the A11+/B62-subgroup, respectively, each exceeding the US WTP threshold of $150,000.00.The combination of toripalimab and chemotherapy was not found to be a costeffective first-line treatment for ES-SCLC in China or the US, except for patients in China with ITH-L and A11+/B62-histology.
Keywords: Cost-Effectiveness, extensive-stage small-cell lung cancer, Toripalimab, chemotherapy, Markov model
Received: 23 Apr 2025; Accepted: 24 Jul 2025.
Copyright: © 2025 Ouyang, Wang, Zhang, Huang, Deng, Deng and Lang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Wenwang Lang, Nanxishan Hospital of Guangxi Zhuang Autonomous Region, Gulin, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.